S9714: Paclitaxel in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
Phase II Trial of Paclitaxel by 96-Hour Infusion in Stage IIIB and IV Bronchioloalveolar Carcinoma (BAC)
Sponsor: National Cancer Institute (NCI)
Listed as NCT00002969, this PHASE2 trial focuses on Lung Cancer and remains completed. Sponsored by National Cancer Institute (NCI), it has been updated 7 times since 1997, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
May 2023 — Jul 2024 [monthly]
Completed PHASE2
-
Jan 2021 — May 2023 [monthly]
Completed PHASE2
▶ Show 2 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE2
First recorded
May 1997
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- National Cancer Institute (NCI)
- SWOG Cancer Research Network
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Albuquerque, United States, Ann Arbor, United States, Atlanta, United States, Billings, United States, Biloxi, United States, Boston, United States, Brooklyn, United States, Cincinnati, United States, Cleveland, United States, Columbus, United States and 46 more location s